Is Tectonic Therapeutic, Inc. (TECX) a Buy, Sell, or Hold?
Tectonic Therapeutic, Inc.
NASDAQ:TECX
$34.81 USD
$0.47 (1.37%)
- Volume
- 266.11K
- Average Volume
- 206.44K
- Market Capitalization
- $656.84M
- P/E Ratio
- -7.80
- Dividend Yield
- 0.00%
- Price Target
- $78.00
- Year High
- $39.53
- Year Low
- $14.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.51
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Alise S. Reicin |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TECX |
| CUSIP | 878972108 |
| CIK | 0001681087 |
| Web | https://tectonictx.com |
| Phone | +1 617 830 5233 |
| Currency | USD |
| Employees | 60 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 18.51 |
| Quick Ratio | 18.51 |
| Cash Ratio | 18.28 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.50 |
| Price / Cash Flow | -10.00 |
| Price / Book | 2.84 |
Price Target and Rating
| Average Stock Price Forecast | $78.00 |
| High Stock Price Forecast | $81.00 |
| Low Stock Price Forecast | $75.00 |
| Forecast Upside/Downside | -55.37% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.05 |
| Trailing P/E Ratio | -7.80 |
| PEG Ratio | -0.27 |
| P/E Growth | -0.27 |
| Net Income | $-74.15M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -32.33% |
| Return on Assets | -33.86% |
Financials Score
| AltmanZ Score | 22.65 |
| Piotroski Score | 1.00 |
| Working Capital | 226.93M |
| Total Assets | 246.58M |
| Ebit | -82.2M |
| Market Cap | 647.97M |
| Total Liabilities | 16.16M |
Poll Results
About Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Wate ... rtown, Massachusetts.
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
2026-06-10 16:01:00
APEX 24-week Phase 2 trial is evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) APEX Phase 2 trial enrolled 191 patients across 14 countries, with approximately 72% of patients in the enriched population of CpcPH with a pulmonary vascular resistance (PVR) >3 WU at baseline TX45 APEX Phase 2 topline results expected in early Q1 2027 WATERTOWN, Mass.
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
2026-06-10 16:01:00
WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced the completion of enrollment for the APEX trial, a 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”). The trial was designed to include an enriched population of a more severe disease subtype of combined pre- and post-capillary pulmonary hypertension (“CpcPH”) patients with a pulmonary vascular resistance (“PVR”)> 3 Wood Units (“WU”) at baseline.
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 16:01:00
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent business highlights.
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
2026-04-23 16:01:00
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026.
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
2026-04-16 07:16:35
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a $0.6B–$1.8B U.S. peak sales opportunity.
Frequently Asked Questions
-
What is the current Tectonic Therapeutic, Inc. (TECX) stock price?
-
Tectonic Therapeutic, Inc.(NASDAQ:TECX) stock price is $34.81 in the last trading session. During the trading session, TECX stock reached the peak price of $39.53 while $14.39 was the lowest point it dropped to. The percentage change in TECX stock occurred in the recent session was 1.37% while the dollar amount for the price change in TECX stock was $0.47.
-
TECX's industry and sector of operation?
-
The NASDAQ listed TECX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TECX?
-
Alise S. Reicin | President, Chief Executive Officer, Secretary & Director
Marc Schwabish | Chief Business Officer
John Diener | Senior Vice President of Antibody Engineering & Protein Sciences
Anthony Muslin | Chief Development Officer
Daniel Lochner | Chief Financial Officer -
How many employees does TECX have?
-
Number of TECX employees currently stands at 60. TECX operates from 490 Arsenal Way, Watertown, MA 02472, US.
-
Link for TECX official website?
-
Official Website of TECX is: https://tectonictx.com
-
How do I contact TECX?
-
TECX could be contacted at phone #+1 617 830 5233 and can also be accessed through its website. TECX operates from 490 Arsenal Way, Watertown, MA 02472, US.
-
How many shares of TECX are traded daily?
-
The average number of TECX shares traded daily for last 3 months was 206.44K.
-
What is the market cap of TECX currently?
-
The market value of TECX currently stands at $656.84M with its latest stock price at $34.81